Effect and mechanism of ertugliflozin on pharmacokinetic of sorafenib and donafenib in rats

DENG Yanru; WANG Zhi; CAO Gexi; YAN Bin; LI Ying; DONG Zhanjun

doi:10.6039/j.issn.1001-0408.2025.07.10

您当前的位置：

首页 >

文章列表页 >

Effect and mechanism of ertugliflozin on pharmacokinetic of sorafenib and donafenib in rats

更新时间：2025-09-23

- Effect and mechanism of ertugliflozin on pharmacokinetic of sorafenib and donafenib in rats
- ZHONGGUO YAOFANG Vol. 36, Issue 7, Pages: 826-831(2025)
- 作者机构：
  
  1.河北省人民医院药学部，石家庄　050051
  2.河北医科大学药学院，石家庄　050017
  3.河北省临床药学重点实验室，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.07.10
  CLC： R969.1
- Received：07 November 2024，
  
  Revised：2025-02-11，
  
  Accepted：12 February 2025，
  
  Published：15 April 2025
- 稿件说明：
移动端阅览
邓艳茹,王智,曹格溪,等.艾托格列净对索拉非尼和多纳非尼在大鼠体内药动学的影响及机制研究 [J].中国药房,2025,36(07):826-831.

DENG Yanru,WANG Zhi,CAO Gexi,et al.Effect and mechanism of ertugliflozin on pharmacokinetic of sorafenib and donafenib in rats[J].ZHONGGUO YAOFANG,2025,36(07):826-831.
邓艳茹,王智,曹格溪,等.艾托格列净对索拉非尼和多纳非尼在大鼠体内药动学的影响及机制研究 [J].中国药房,2025,36(07):826-831. DOI： 10.6039/j.issn.1001-0408.2025.07.10.

DENG Yanru,WANG Zhi,CAO Gexi,et al.Effect and mechanism of ertugliflozin on pharmacokinetic of sorafenib and donafenib in rats[J].ZHONGGUO YAOFANG,2025,36(07):826-831. DOI： 10.6039/j.issn.1001-0408.2025.07.10.

摘要

目的

研究艾托格列净对索拉非尼和多纳非尼在大鼠体内药动学的影响，并探究相关机制。

方法

将24只雄性SD大鼠随机分成4组，每组6只。A、B组大鼠连续7 d分别灌胃0.5%羧甲基纤维素钠和艾托格列净（1.5 mg/kg），第7天给药后均灌胃索拉非尼（100 mg/kg）；C、D组大鼠前7 d灌胃处理分别与A、B组一致，在第7天给药后均灌胃多纳非尼（40 mg/kg）。各组大鼠于索拉非尼或多纳非尼给药前和给药后不同时间点采集血样，采用超高效液相色谱-串联质谱法分别测定A、B组大鼠血浆中索拉非尼质量浓度和C、D组大鼠血浆中多纳非尼质量浓度，利用DAS 2.1.1软件计算药动学参数。另取6只大鼠随机分为空白对照组和艾托格列净给药组，每组3只。空白对照组大鼠灌胃0.5%羧甲基纤维素钠，艾托格列净给药组大鼠灌胃艾托格列净（1.5 mg/kg），每天1次，连续7 d。末次给药后，检测大鼠肝脏和小肠组织中尿苷二磷酸葡萄糖醛酸转移酶1A7（UGT1A7）、乳腺癌耐药蛋白（BCRP）和P-糖蛋白（P-gp）mRNA表达水平。

结果

与A组比较，B组大鼠血浆中索拉非尼的药-时曲线下面积（AUC

）、AUC

0-∞

、峰浓度（

max

）、达峰时间（

max

）、平均滞留时间（MRT

）、MRT

0-∞

均显著降低（

＜0.05），清除率（CL）和表观分布容积（

）均显著升高（

＜0.05）；与C组比较，D组大鼠血浆中多纳非尼的AUC

、AUC

0-∞

、

max

、

max

、MRT

均显著降低（

＜0.05），

和CL均显著升高（

＜0.05）。连续7 d灌胃艾托格列净对大鼠肝脏和小肠组织中UGT1A7、P-gp、BCRP mRNA的表达无显著影响。

结论

艾托格列净可影响索拉非尼和多纳非尼在大鼠体内的药动学过程，减少两者的体内暴露量，但其作用机制可能并非是通过调控相关代谢酶和转运体；临床联合用药时应警惕药物治疗效果不佳可能导致的疾病进展。

Abstract

OBJECTIVE

To investigate the effects of ertugliflozin on pharmacokinetic of sorafenib and donafenib in rats and explore the mechanism.

METHODS

Twenty-four male SD rats were randomly divided into four groups， with 6 rats in each group. Groups A and B were respectively gavaged with 0.5% sodium carboxymethyl cellulose solution and ertugliflozin （1.5 mg/kg） for 7 consecutive days， and both were given sorafenib （100 mg/kg） on the 7th day. Groups C and D were administered intragastrically in the same way as those in Groups A and B， respectively， for the first 7 days； after the drug administration on the 7th day， all rats in Groups C and D were further gavaged with donafenib （40 mg/kg）. Blood samples were collected at different time points before and after administration of sorafenib or donafenib， the concentrations of sorafenib in plasma of rats in groups A and B and donafenib in groups C and D were determined by UPLC-MS/MS method. The pharmacokinetic parameters were calculated by DAS 2.1.1 software. Six additional rats were randomly divided into blank control group and ertugliflozin group， with three rats in each group. Blank control group was given 0.5% sodium carboxymethyl cellulose intragastrically， while rats in ertugliflozin group were given ertugliflozin （1.5 mg/kg） once a day for 7 consecutive days. After the last administration， the mRNA expression levels of uridine diphosphate glucuronosyl transferase 1A7 （UGT1A7）， breast cancer resistance protein （BCRP）， and P-glycoprotein （P-gp） in the liver and small intestine tissues of the rats were detected.

RESULTS

Compared with group A， the AUC

， AUC

0-∞

，

max

，

max

， MRT

and MRT

0-∞

of sorafenib in group B were decreased significantly， while CL and

were increased significantly. Compared with group C， the AUC

， AUC

0-∞

，

max

，

max

and MRT

of donafenib in group D were decreased significantly， while

and CL were increased significantly （

＜0.05）. mRNA expression of UGT1A7， P-gp and BCRP in the liver tissue and small intestine of rats were not significantly affected after intragastric administration of ertugliflozin for 7 consecutive days.

CONCLUSIONS

Ertugliflozin can affect the pharmacokinetics of sorafenib and donafenib in rats and decrease the plasma exposure of them significantly. However， its mechanism of action may not be through the regulation of related metabolic enzymes and transporters. When using drugs in combination clinically， one should be vigilant about the potential for disease progression due to poor therapeutic effects.

关键词

Keywords

references

国家卫生健康委员会 . 原发性肝癌诊疗指南：2024年版 [J ] . 临床肝胆病杂志， 2024 ， 40 （ 5 ）： 893 - 918 .

邹瑜斌，杨灵，肖池金 . 卡瑞利珠单抗联合索拉非尼治疗晚期肝癌的临床观察 [J ] . 中国药房， 2024 ， 35 （ 12 ）： 1522 - 1526 .

李时，石亚飞，贾贝，等 . 基于OpenVigil对索拉非尼和瑞戈非尼不良事件的信号挖掘与分析 [J ] . 肿瘤药学， 2024 ， 14 （ 3 ）： 350 - 359 .

秦叔逵，沈锋，周俭 . 多纳非尼治疗肝细胞癌临床应用专家共识 [J ] . 临床肿瘤学杂志， 2022 ， 27 （ 8 ）： 749 - 757 .

PEER C J ， SISSUNG T M ， KIM A ， et al . Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9：implications of genetic variants on pharmacokinetics and hyperbilirubinemia [J ] . Clin Cancer Res ， 2012 ， 18 （ 7 ）： 2099 - 2107 .

KEAM S J ， DUGGAN S . Donafenib：first approval [J ] . Drugs ， 2021 ， 81 （ 16 ）： 1915 - 1920 .

LI X ， WANG X C ， GAO P J . Diabetes mellitus and risk of hepatocellular carcinoma [J ] . Biomed Res Int ， 2017 ， 2017 ： 5202684 .

SIMON T G ， KING L Y ， CHONG D Q ， et al . Diabetes，metabolic comorbidities，and risk of hepatocellular carcinoma：results from two prospective cohort studies [J ] . Hepatology ， 2018 ， 67 （ 5 ）： 1797 - 1806 .

GU N ， PARK S I ， CHUNG H ， et al . Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor [J ] . Transl Clin Pharmacol ， 2020 ， 28 （ 1 ）： 17 - 33 .

程钱，邹舒鹏，孙明辉 . 新一代钠-葡萄糖共转运体-2抑制剂艾托格列净在糖尿病及特殊人群中的治疗价值 [J ] . 中国新药杂志， 2023 ， 32 （ 11 ）： 1099 - 1107 .

国家老年医学中心，中华医学会老年医学分会，中国老年保健协会糖尿病专业委员会 . 中国老年糖尿病诊疗指南： 2024版 [J ] . 协和医学杂志， 2024 ， 15 （ 4 ）： 771 - 800 .

刘洪涛，张磊，黄志云，等 . 水飞蓟宾对索拉非尼在大鼠体内药动学的影响及机制研究 [J ] . 中草药， 2023 ， 54 （ 21 ）： 7104 - 7110 .

KARBOWNIK A ， MIEDZIASZCZYK M ， GRABOWSKI T ， et al . In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol [J ] . Biomed Pharmacother ， 2020 ， 130 ： 110530 .

KARBOWNIK A ， SZKUTNIK-FIEDLER D ， GRABOWSKI T ， et al . Pharmacokinetic drug interaction study of sorafenib and morphine in rats [J ] . Pharmaceutics ， 2021 ， 13 （ 12 ）： 2172 .

LEBLANC T W ， MCNEIL M J ， KAMAL A H ， et al . Polypharmacy in patients with advanced cancer and the role of medication discontinuation [J ] . Lancet Oncol ， 2015 ， 16 （ 7 ）： e333-41 .

CHENG J J ， AZIZODDIN A M ， MARANZANO M J ， et al . Polypharmacy in oncology [J ] . Clin Geriatr Med ， 2022 ， 38 （ 4 ）： 705 - 714 .

KONI A A ， NAZZAL M A ， SUWAN B A ， et al . A comprehensive evaluation of potentially significant drug-drug，drug-herb，and drug-food interactions among cancer patients receiving anticancer drugs [J ] . BMC Cancer ， 2022 ， 22 （ 1 ）： 547 .

VASILYEVA A ， DURMUS S ， LI L ， et al . Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2，Abcc3，and Oatp1a/1b [J ] . Cancer Res ， 2015 ， 75 （ 13 ）： 2729 - 2736 .

CHEN M Q ， NEUL C ， SCHAEFFELER E ， et al . Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 [J ] . Clin Pharmacol Ther ， 2020 ， 107 （ 1 ）： 227 - 237 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of disodium cantharidinate on the pharmacokinetic behavior of capecitabine in rats

Establishment of content determination of 5 saponins in Huoxue zhitong capsules/tablets and confirmation of illegal addition

UPLC-MS/MS法同时测定人血浆中阿魏酸和芍药苷的含量

Pharmacokinetic difference of Shenxiong glucose injection in normal and acute myocardial ischemia rats

Simultaneous determination of 10 constituents in Huoxiang zhengqi soft capsules by UPLC-MS/MS

Related Author

HUANG Jing

BAN Yujuan

CHEN Rui

HU Kerong

ZHANG Ling

CAO Yu

SHI Da

CHEN Jie

Related Institution

School of Pharmacy， Guizhou Medical University

Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D

School of Pharmacy， Nanjing Medical University

Nanjing Institute for Food and Drug Control

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰